Revascular Bio addresses
the magical power
of blood vessels
Maximize the vascular potential and deliver it to the lives of patients around the world
Disorders of "blood vessels" that spread throughout the body cause various diseases, and there is still no effective treatment for disorders of microscopic blood vessels. We aim to solve these diseases by developing cell therapy using vascular endothelial stem cells.
Chronic wounds (intractable skin ulcers), severe lower limb ischemia, cerebrovascular dementia, breast reconstruction therapy, hemophilia, lysosomal diseases
"Angiogenesis therapy" recovers micro-blood flow disorders by transplanting vascular endothelial stem cells, "angiocrine therapy" permanently supplies proteins damaged by gene-deficient diseases and utilizes gene editing technology. The "Protein Production/Secretion Platform" will enable the realization of various groundbreaking treatments
Collaborator : Nobuyuki Takakura, M.D., Ph.D.
Professor, Research Institute for Microbial Diseases, Osaka University
Endothelial cells, which form the lumen of blood vessels, serve as an interface between tissue cells and blood flow within the body, and not only maintain homeostasis by supplying humoral signals, but also play a central role in the coordination mechanism of the whole body through organ connections. We have shown that the stem cell system within the blood vessel itself is essential for this intravascular turnover of vascular endothelial cells, and that by controlling these vascular endothelial stem cells, unprecedented organ reconstruction becomes possible. By utilizing the role of vascular endothelial stem cells as a control tower for the general state of the body, we will take on the challenge of developing new treatments for genetic deficiency diseases for which there are currently no radical treatments and for suppressing the growth of cancer over the long term.
Endothelial cells (ECs) are designated as CD31+CD45- cells (upper left). We found that CD157positive ECs are EC stem cells in the pre-existing blood vessels in all argans. In liver,CD157+CD200+ ECs represent stemness (lower left) and they have potential to regenerate sustainable blood vessels (sinusoids) in liver injury model (right). In other organs, CD157+ ECs show revascularization ability in many disease models including such as ischemic diseases and genetic diseases.
We have discovered that vascular endothelial stem cells exist in pre-existing blood vessels, which maintain organ-specific vascular structures and functions, and rapidly rebuild blood vessels when damaged. (Wakabayashi et al. Cell Stem Cell 2018, Naito et al. Nature Protocol 2020). In recent years, genetic analysis of tissue cells of various organs using single cell RNA sequencing has been actively conducted. As a result, gene expression specific to arteries, veins, and capillaries has been observed among vascular endothelial cells, moreover, it has been revealed that there are endothelial cells having potential to show tissue/organ specific function. It is thought that such heterogeneity of vascular endothelial cells is maintained by vascular endothelial stem cells. Recently, we have clarified the development and age-related changes of vascular endothelial stem cells (Rahmawati FN et al. Stem Cell Research & Therapy 2023, Shimizu et a. Angiogenesis 2023). Based on utilizing such results from basic research, we challenge to manipulate efficient and sustainable vascular regeneration through vascular endothelial stem cell transplantation.
Revascular Bio Co., Ltd.
September 8, 2022
Kazuo Omori, Representative Director, President and CEO
April 1 to March 31
5 (as of November 10, 2023)
3-1 Yamadaoka, Suita, Osaka 565-0871